Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

1287030

USP

Furosemide Related Compound B

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

4-Chloro-5-sulfamoylanthranilic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C7H7ClN2O4S
Numéro CAS:
3086-91-7
Poids moléculaire :
250.66
Numéro MDL:
MFCD03423689
Code UNSPSC :
41116107
ID de substance PubChem :
329749918
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

furosemide

Fabricant/nom de marque

USP

Pf

267 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

Nc1cc(Cl)c(cc1C(O)=O)S(N)(=O)=O

InChI

1S/C7H7ClN2O4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,9H2,(H,11,12)(H2,10,13,14)

Clé InChI

QQLJBZFXGDHSRU-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Furosemide Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

F0700000

Furosemide, European Pharmacopoeia (EP) Reference Standard

1287008

Furosemide, United States Pharmacopeia (USP) Reference Standard

F0702000

Furosemide impurity A, European Pharmacopoeia (EP) Reference Standard

1287020

Furosemide Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1057

Furosemide, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001493

Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard

BP547

Furosemide, British Pharmacopoeia (BP) Reference Standard

BP074

4-Chloro-5-sulfamoylanthranilic acid, British Pharmacopoeia (BP) Reference Standard

PHR2457

2,4-Dichlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Environment
GHS09

Mentions de danger

H411

Conseils de prudence

P273

Classification des risques

Aquatic Chronic 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

[Determination of furosemide and its metabolic products in plasma and urine by high performance liquid chromatography and clinical application].
Y Miwa et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 108(11), 1087-1092 (1988-11-01)
D E Smith et al.
Drug metabolism and disposition: the biological fate of chemicals, 8(5), 337-342 (1980-09-01)
The objectives of this study were to qualitatively and quantitatively compare the metabolism, pharmacokinetics, and bioavailability of furosemide in healthy volunteers after intravenous and oral administration. We also determined the plasma protein binding of furosemide in vivo after iv administration.
G M Hanna et al.
Journal of AOAC International, 76(3), 526-530 (1993-05-01)
A simple, specific, and accurate proton nuclear magnetic resonance (1H-NMR) spectroscopic method has been developed for the identification and assay of furosemide and its degradation product, 4-chloro-5-sulfamoylanthranilic acid (CSA), in tablets and injections. Dissolution of the sample in D2O-NaOD resulted
H Nakahama et al.
European journal of clinical pharmacology, 32(3), 313-315 (1987-01-01)
Urine from 5 renal transplant recipients treated with frusemide was analyzed for unchanged frusemide (F), glucuronidated frusemide (G) and 4-chloro-5-sulfamoylanthranilic acid (CSA) by HPLC. In 3 recipients, whose renal function recovered steadily and whose hepatic function was normal throughout, the
L Z Benet et al.
Federation proceedings, 42(6), 1695-1698 (1983-04-01)
A variety of furosemide assays and their application to biological samples have been described over the past 2 decades. We describe development of a specific, sensitive assay appropriate for efficient measurement of large numbers of biological samples. With development of
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique